Exon-skipping drugs present a critical test for the FDA’s goal of encouraging treatments for rare disease.
BriefSTAT News
STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate few
BriefSTAT News
Exon-skipping drugs present a critical test for the FDA’s goal of encouraging treatments for rare disease.